Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
la/mBC - HER2 positive, trastuzumab based treatment vs. TKI anti HER1/EGFR and HER2/neu, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.62 [0.30; 1.27]
0.62 [0.30 ; 1.27 ] NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 1 0% 301 NA not evaluable deaths (OS) (extension)detailed results ALTTO (T plus L vs T), 2020 0.86 [0.70; 1.06]
NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.72 [0.41; 1.27]
NeoALTTO (lapatinib vs trastuzumab), 2012 0.85 [0.49; 1.47]
0.84 [0.70 ; 1.01 ] ALTTO (T plus L vs T), 2020, NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012, NeoALTTO (lapatinib vs trastuzumab), 2012 3 0% 4,794 moderate not evaluable RFS/DFSdetailed results ALTTO (T plus L vs T), 2020 0.84 [0.70; 1.01]
0.84 [0.70 ; 1.01 ] ALTTO (T plus L vs T), 2020 1 0% 4,190 NA not evaluable events or deaths (EFS)detailed results NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.78 [0.47; 1.29]
0.78 [0.47 ; 1.29 ] NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 1 0% 301 NA not evaluable events or deaths (EFS) (extended)detailed results NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.81 [0.52; 1.26]
NeoALTTO (lapatinib vs trastuzumab), 2012 0.98 [0.64; 1.51]
0.89 [0.66 ; 1.22 ] NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012, NeoALTTO (lapatinib vs trastuzumab), 2012 2 0% 604 moderate not evaluable pCR detailed results NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 2.60 [1.49; 4.54]
NeoALTTO (lapatinib vs trastuzumab), 2012 0.78 [0.47; 1.30]
1.42 [0.44 ; 4.60 ] NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012, NeoALTTO (lapatinib vs trastuzumab), 2012 2 90% 604 moderate not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 11:53 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 355,337,146,317
- treatments: 1299,1334,1332,1303,1325,1320,1305,1300,1429,1324,1335,1307,1322